Hypercoagulable states: An algorithmic approach to laboratory testing and update on monitoring of direct oral anticoagulants

Blood Research

Volumn 49, Issue 2, 2014, Pages 85-94

  Nakashima, Megan O ^a   Rogers, Heesun J ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Algorithmic approach; Antiphospholipid syndrome; Direct oral anticoagulant; Hypercoagulability; Venous thromboembolism

Indexed keywords

ANTICOAGULANT AGENT; B2GP1 PROTEIN ANTIBODY; BLOOD CLOTTING FACTOR 5 LEIDEN; BLOOD CLOTTING FACTOR 8; CARDIOLIPIN ANTIBODY; LUPUS ANTICOAGULANT; PROTEIN ANTIBODY; PROTHROMBIN; UNCLASSIFIED DRUG;

ACTIVATED PROTEIN C RESISTANCE; ALGORITHM; ANTIPHOSPHOLIPID SYNDROME; ANTITHROMBIN DEFICIENCY; DRUG MONITORING; FIBRINOGEN DEFECT; GENE MUTATION; HUMAN; HYPERCOAGULABILITY; HYPERHOMOCYSTEINEMIA; LABORATORY PERSONNEL; LABORATORY TEST; MEDICAL HISTORY; PROTEIN C DEFICIENCY; PROTEIN S DEFICIENCY; REVIEW;

EID: 84903550313     PISSN: 2287979X     EISSN: 22880011     Source Type: Journal    
DOI: 10.5045/br.2014.49.2.85     Document Type: Review

References (78)

1. Olson JD, Eby C. Arterial and venous thrombosis in adults. In: Kottke-Marchant K, ed. An algorithmic approach to hemostasis testing. 1st ed. Northfield, IL: College of American Pathologists, 2008:239-66.
2. Margetic S. Diagnostic algorithm for thrombophilia screening. Clin Chem Lab Med 2010;48(Suppl 1):S27-39.
3. Kottke-Marchant K. Laboratory diagnosis of hemorrhagic and thrombotic disorders. Hematol Oncol Clin North Am 1994;8:809-53.
4. Khor B, Van Cott EM. Laboratory evaluation of hypercoagulability. Clin Lab Med 2009;29:339-66.
5. Heit JA. Thrombophilia: common questions on laboratory assessment and management. Hematology Am Soc Hematol Educ Program 2007:127-35.
6. Baglin T, Gray E, Greaves M, et al. Clinical guidelines for testing for heritable thrombophilia. Br J Haematol 2010;149:209-20.
7. Eby C. Laboratory diagnosis of inherited thrombophilia. In: Kottke-Marchant K, ed. An algorithmic approach to hemostasis testing. 1st ed. Northfield, IL: College of American Pathologists, 2008:267-77.
8. Middeldorp S. Evidence-based approach to thrombophilia testing. J Thromb Thrombolysis 2011;31:275-81.
9. Van Cott EM, Eby C. Antiphospholipid antibodies. In: Kottke-Marchant K, ed. An algorithmic approach to hemostasis testing. 1st ed. Northfield, IL: College of American Pathologists, 2008:295-304.
10. Miyakis S, Lockshin MD, Atsumi T, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006;4: 295-306.
11. Pengo V, Tripodi A, Reber G, et al. Update of the guidelines for lupus anticoagulant detection. J Thromb Haemost 2009;7:1737-40.
12. Finazzi G, Brancaccio V, Moia M, et al. Natural history and risk factors for thrombosis in 360 patients with antiphospholipid antibodies: a four-year prospective study from the Italian Registry. Am J Med 1996;100:530-6.
13. Brandt JT, Triplett DA, Alving B, Scharrer I. Criteria for the diagnosis of lupus anticoagulants: an update. On behalf of the Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the ISTH. Thromb Haemost 1995;74:1185-90.
14. Reber G, de Moerloose P. Anti-beta2-glycoprotein I antibodieswhen and how should they be measured? Thromb Res 2004;114: 527-31.
15. Nichols WL, Kottke-Marchant K, Ledford-Kraemer MR, Homburger HA, Cardel LK. Lupus anticoagulants, antiphospholipid antibodies, and antiphospholipid syndrome. In: Kottke-Marchant K, Davis BH, eds. Laboratory hematology practice. West Sussex, UK: Wiley-Blackwell Publishing ltd, 2012:509-25.
16. Keeling D, Mackie I, Moore GW, Greer IA, Greaves M. Guidelines on the investigation and management of antiphospholipid syndrome. Br J Haematol 2012;157:47-58.
17. Ledford-Kraemer MR, Moore GW, Bottenus R, et al, eds. Laboratory testing for the lupus anticoagulant; Approved guideline. CLSI document H60. Wayne, PA: Clinical and Laboratory Standards Institute, 2014.
18. Yohe S, Olson J. Thrombophilia: assays and interpretation. In: Kottke-Marchant K, Davis BH, eds. Laboratory hematology practice. West Sussex, UK: Wiley-Blackwell Publishing ltd, 2012:492-508.
19. Moffat KA, Ledford-Kraemer MR, Plumhoff EA, et al. Are laboratories following published recommendations for lupus anticoagulant testing? An international evaluation of practices. Thromb Haemost 2009;101:178-84.
20. Triplett DA. Antiphospholipid antibodies. Arch Pathol Lab Med 2002;126:1424-9.
21. Galli M, Luciani D, Bertolini G, Barbui T. Anti-beta 2-glycoprotein I, antiprothrombin antibodies, and the risk of thrombosis in the antiphospholipid syndrome. Blood 2003;102:2717-23.
22. Marai I, Gilburd B, Blank M, Shoenfeld Y. Anti-cardiolipin and anti-beta2-glycoprotein I (beta2GP-I) antibody assays as screening for anti-phospholipid syndrome. Hum Antibodies 2003;12: 57-62.
23. Rosendaal FR, Koster T, Vandenbroucke JP, Reitsma PH. High risk of thrombosis in patients homozygous for factor V Leiden (activated protein C resistance). Blood 1995;85:1504-8.
24. Zivelin A, Griffin JH, Xu X, et al. A single genetic origin for a common Caucasian risk factor for venous thrombosis. Blood 1997;89:397-402.
25. Ridker PM, Miletich JP, Hennekens CH, Buring JE. Ethnic distribution of factor V Leiden in 4047 men and women. Implications for venous thromboembolism screening. JAMA 1997;277:1305-7.
26. Greengard JS, Sun X, Xu X, Fernandez JA, Griffin JH, Evatt B. Activated protein C resistance caused by Arg506Gln mutation in factor Va. Lancet 1994;343:1361-2.
27. Chan WP, Lee CK, Kwong YL, Lam CK, Liang R. A novel mutation of Arg306 of factor V gene in Hong Kong Chinese. Blood 1998; 91:1135-9.
28. Franco RF, Elion J, Tavella MH, Santos SE, Zago MA. The prevalence of factor V Arg306-->Thr (factor V Cambridge) and factor V Arg306-->Gly mutations in different human populations. Thromb Haemost 1999;81:312-3.
29. Norstrom E, Thorelli E, Dahlback B. Functional characterization of recombinant FV Hong Kong and FV Cambridge. Blood 2002;100:524-30.
30. Press RD, Bauer KA, Kujovich JL, Heit JA. Clinical utility of factor V leiden (R506Q) testing for the diagnosis and management of thromboembolic disorders. Arch Pathol Lab Med 2002;126:1304-18.
31. Ledford M, Friedman KD, Hessner MJ, Moehlenkamp C, Williams TM, Larson RS. A multi-site study for detection of the factor V (Leiden) mutation from genomic DNA using a homogeneous invader microtiter plate fluorescence resonance energy transfer (FRET) assay. J Mol Diagn 2000;2:97-104.
32. Murugesan G, Jans S, Han JY. Single nucleotide polymorphisms in molecular diagnostics. In: Kottke-Marchant K, Davis BH, eds. Laboratory hematology practice. West Sussex, UK: Wiley-Blackwell Publishing ltd, 2012:168-80.
33. McGlennen RC, Key NS. Clinical and laboratory management of the prothrombin G20210A mutation. Arch Pathol Lab Med 2002;126:1319-25.
34. Rosendaal FR, Doggen CJ, Zivelin A, et al. Geographic distribution of the 20210 G to A prothrombin variant. Thromb Haemost 1998;79:706-8.
35. Ballard RB, Marques MB. Pathology consultation on the laboratory evaluation of thrombophilia: when, how, and why. Am J Clin Pathol 2012;137:553-60.
36. Poort SR, Rosendaal FR, Reitsma PH, Bertina RM. A common genetic variation in the 3'-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 1996;88:3698-703.
37. Khor B, Van Cott EM. Laboratory tests for protein C deficiency. Am J Hematol 2010;85:440-2.
38. Van Cott EM, Laposata M, Prins MH. Laboratory evaluation of hypercoagulability with venous or arterial thrombosis. Arch Pathol Lab Med 2002;126:1281-95.
39. Maurissen LF, Thomassen MC, Nicolaes GA, et al. Re-evaluation of the role of the protein S-C4b binding protein complex in activated protein C-catalyzed factor Va-inactivation. Blood 2008;111:3034-41.
40. Rosing J, Maurissen LF, Tchaikovski SN, Tans G, Hackeng TM. Protein S is a cofactor for tissue factor pathway inhibitor. Thromb Res 2008;122:S60-3.
41. Dykes AC, Walker ID, McMahon AD, Islam SI, Tait RC. A study of Protein S antigen levels in 3788 healthy volunteers: influence of age, sex and hormone use, and estimate for prevalence of deficiency state. Br J Haematol 2001;113:636-41.
42. Aillaud MF, Pouymayou K, Brunet D, et al. New direct assay of free protein S antigen applied to diagnosis of protein S deficiency. Thromb Haemost 1996;75:283-5.
43. Castoldi E, Hackeng TM. Regulation of coagulation by protein S. Curr Opin Hematol 2008;15:529-36.
44. Ten Kate MK, Platteel M, Mulder R, et al. PROS1 analysis in 87 pedigrees with hereditary protein S deficiency demonstrates striking genotype-phenotype associations. Hum Mutat 2008;29: 939-47.
45. Mackie I, Cooper P, Lawrie A, Kitchen S, Gray E, Laffan M. Guidelines on the laboratory aspects of assays used in haemostasis and thrombosis. Int J Lab Hematol 2013;35:1-13.
46. Vossen CY, Conard J, Fontcuberta J, et al. Familial thrombophilia and lifetime risk of venous thrombosis. J Thromb Haemost 2004;2:1526-32.
47. Rogers HJ, Kottke-Marchant K. Antithrombin deficiency. In: Gulati G, Filicko-O'Hara J, Krause JR, eds. Case studies in hematology and coagulation. Chicago, IL: American Society for Clinical Pathology Press, 2012:416-8.
48. Kottke-Marchant K, Duncan A. Antithrombin deficiency: issues in laboratory diagnosis. Arch Pathol Lab Med 2002;126:1326-36.
49. Picard V, Nowak-Gottl U, Biron-Andreani C, et al. Molecular bases of antithrombin deficiency: twenty-two novel mutations in the antithrombin gene. Hum Mutat 2006;27:600.
50. Khor B, Van Cott EM. Laboratory tests for antithrombin deficiency. Am J Hematol 2010;85:947-50.
51. Rao AK, Niewiarowski S, Guzzo J, Day HJ. Antithrombin III levels during heparin therapy. Thromb Res 1981;24:181-6.
52. Guba SC, Fonseca V, Fink LM. Hyperhomocysteinemia and thrombosis. Semin Thromb Hemost 1999;25:291-309.
53. Eldibany MM, Caprini JA. Hyperhomocysteinemia and thrombosis: an overview. Arch Pathol Lab Med 2007;131:872-84.
54. Ray JG, Shmorgun D, Chan WS. Common C677T polymorphism of the methylenetetrahydrofolate reductase gene and the risk of venous thromboembolism: meta-analysis of 31 studies. Pathophysiol Haemost Thromb 2002;32:51-8.
55. Den Heijer M, Lewington S, Clarke R. Homocysteine, MTHFR and risk of venous thrombosis: a meta-analysis of published epidemiological studies. J Thromb Haemost 2005;3:292-9.
56. Hickey SE, Curry CJ, Toriello HV. ACMG Practice Guideline: lack of evidence for MTHFR polymorphism testing. Genet Med 2013;15:153-6.
57. O'Donnell J, Mumford AD, Manning RA, Laffan M. Elevation of FVIII: C in venous thromboembolism is persistent and independent of the acute phase response. Thromb Haemost 2000;83:10-3.
58. Oger E, Lacut K, Van Dreden P, et al. High plasma concentration of factor VIII coagulant is also a risk factor for venous thromboembolism in the elderly. Haematologica 2003;88:465-9.
59. Ota S, Yamada N, Ogihara Y, et al. High plasma level of factor VIII: an important risk factor for venous thromboembolism. Circ J 2011;75:1472-5.
60. Jenkins PV, Rawley O, Smith OP, O'Donnell JS. Elevated factor VIII levels and risk of venous thrombosis. Br J Haematol 2012;157:653-63.
61. Kraaijenhagen RA, in't Anker PS, Koopman MM, et al. High plasma concentration of factor VIIIc is a major risk factor for venous thromboembolism. Thromb Haemost 2000;83:5-9.
62. Kyrle PA, Minar E, Hirschl M, et al. High plasma levels of factor VIII and the risk of recurrent venous thromboembolism. N Engl J Med 2000;343:457-62.
63. Benjaber K, Constans J, Cougnard A, Salmi LR. High levels of factor VIIIc and risk of venous thrombosis: critical analysis of case-control studies. Rev Med Interne 2003;24:366-71.
64. Haverkate F, Samama M. Familial dysfibrinogenemia and thrombophilia. Report on a study of the SSC Subcommittee on Fibrinogen. Thromb Haemost 1995;73:151-61.
65. Cunningham MT, Brandt JT, Laposata M, Olson JD. Laboratory diagnosis of dysfibrinogenemia. Arch Pathol Lab Med 2002;126: 499-505.
66. Hayes T. Dysfibrinogenemia and thrombosis. Arch Pathol Lab Med 2002;126:1387-90.
67. Verhovsek M, Moffat KA, Hayward CP. Laboratory testing for fibrinogen abnormalities. Am J Hematol 2008;83:928-31.
68. Mani H, Kasper A, Lindhoff-Last E. Measuring the anticoagulant effects of target specific oral anticoagulants-reasons, methods and current limitations. J Thromb Thrombolysis 2013;36:187-94.
69. Eby C. Novel anticoagulants and laboratory testing. Int J Lab Hematol 2013;35:262-8.
70. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009;361:1139-51.
71. Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011;365:981-92.
72. Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011;365:883-91.
73. Steiner T, Bohm M, Dichgans M, et al. Recommendations for the emergency management of complications associated with the new direct oral anticoagulants (DOACs), apixaban, dabigatran and rivaroxaban. Clin Res Cardiol 2013;102:399-412.
74. Baglin T, Hillarp A, Tripodi A, Elalamy I, Buller H, Ageno W. Measuring oral direct inhibitors (ODIs) of thrombin and factor Xa: a recommendation from the Subcommittee on Control of Anticoagulation of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis. J Thromb Haemost 2013;11:756-60.
75. Harenberg J, Marx S, Weiss C, Kramer R, Samama M, Schulman S. Report of the Subcommittee of Control of Anticoagulation on the determination of the anticoagulant effects of rivaroxaban. J Thromb Haemost 2012;10:1433-6.
76. Harenberg J, Du S, Weiss C, Kramer R, Hoppensteadt D, Walenga J. Report of the Subcommittee on Control of Anticoagulation on the determination of the anticoagulant effects of apixaban: communication from the SSC of the ISTH. J Thromb Haemost 2014;12:801-4.
77. Mani H. Interpretation of coagulation test results under direct oral anticoagulants. Int J Lab Hematol 2014;36:261-8.
78. Nowak G. The ecarin clotting time, a universal method to quantify direct thrombin inhibitors. Pathophysiol Haemost Thromb 2003;33:173-83.